<DOC>
	<DOCNO>NCT00495131</DOCNO>
	<brief_summary>Chronic hepatitis C virus ( HCV ) infection prevalent world , affect 3 % world 's population . The current standard therapy pegylated interferon ribavirin , reach 54-63 % successful rate . In patient HCV genotype 1 infection , 48 week course combination therapy achieve high successful rate 24 week course therapy . However , several study Taiwan show 24 week course therapy comparable even good response 48 week course therapy Western country . Therefore , whether 48 week course therapy achieve high response 24 week course therapy Taiwanese patient genotype 1 HCV infection remain unclear .</brief_summary>
	<brief_title>Randomized Trial 24 48 Weeks Peginterferon Alfa-2a Plus Ribavirin HCV Genotype 1-infected Patients</brief_title>
	<detailed_description>Combination therapy interferon alfa ( IFN-α ) plus ribavirin 24 48 week produce sustained virologic response ( SVR ) rate approximately 31-47 % treatment naïve patient chronic hepatitis C. ( 1-5 ) Patients genotype 1 virus infection less likely SVR genotype infection , therefore , patient infect hepatitis C virus ( HCV ) genotype 1 receive treatment 48 week . ( 6 ) Recently , combination therapy pegylated interferon alfa ( pegylated IFN-α ) plus ribavirin produce high SVR rate ( 54-56 % ) IFN-α plus ribavirin . ( 7,8 ) Furthermore , large trial assess effect duration pegylated IFN-α plus ribavirin show overall SVR rate 63 % . Among patient genotype 1 HCV infection , standard dose ribavirin ( 1000 1200 mg per day ) 48 week treatment significantly effective low dose ribavirin ( 800 mg per day ) 24 week treatment . ( 9 ) The SVR rate 51 % genotype 1 patient receive pegylated IFN-α plus standard dose ribavirin 48 week , whereas 29 % 41 % receiving pegylated IFN-α plus low dose ribavirin standard dose ribavirin 24 week , respectively . Based line evidence , 48 week therapy pegylated IFN-α ( pegylated IFN-α 2a 180 μg pegylated IFN-α 2b 1.5 μg per kilogram body weight weekly ) plus ribavirin ( 1000 1200 mg per day ) recommend treat patient HCV genotype 1 infection . ( 10 ) In Taiwan , multicenter study show 6 month course treatment pegylated IFN-α plus standard dose ribavirin comparable SVR rate IFN-α plus standard dose ribavirin ( 67.1 % versus 63.6 % ) patient chronic hepatitis C. Subgroup analysis show treatment pegylated IFN-α plus standard dose ribavirin significantly high SVR rate IFN-α plus standard dose ribavirin ( 65.8 % versus 41.0 % ) patient genotype 1 HCV infection . ( 11 ) Recently , pilot study compare 24 48 week pegylated IFN-α plus standard dose ribavirin patient genotype 1 HCV infection show 48 week treatment efficacious 24 week treatment ( SVR rate : 80.0 % versus 48.9 % ) . ( 12 ) However , much difference SVR rate occur two study , make optimal therapy Taiwanese patient infect genotype 1 HCV difficult determine . In study , aim investigate large cohort whether 48 week treatment pegylated IFN-α plus standard dose ribavirin efficacious 24 week treatment patient genotype 1 HCV infection .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Treatment naïve Age 18 old 18 year old AntiHCV ( Abbott HCV EIA 2.0 , Abbott Diagnostic , Chicago , IL ) positive &gt; 6 month Detectable serum quantitative HCVRNA ( Cobas Amplicor HCV Monitor v2.0 , Roche Molecular Systems , Pleasanton , CA ) dynamic range 600~ &lt; 500,000 IU/ml HCV genotype 1 ( InnoLiPA HCV II , Innogenetics , Ghent , Belgium ) Serum alanine aminotransferase level upper limit normal 6 month enrollment A liver biopsy consistent diagnosis chronic hepatitis C Anemia ( hemoglobin &lt; 13 gram per deciliter men &lt; 12 gram per deciliter woman ) Neutropenia ( neutrophil count &lt; 1,500 per cubic milliliter ) Thrombocytopenia ( platelet &lt; 90,000 per cubic milliliter ) Coinfection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Chronic alcohol abuse ( daily consumption &gt; 20 gram per day ) Decompensated liver disease ( ChildPugh class B C ) Serum creatinine level 1.5 time upper limit normal Autoimmune liver disease Neoplastic disease An organ transplant Immunosuppressive therapy Poorly control autoimmune disease , pulmonary disease , cardiac disease , psychiatric disease , neurological disease , diabetes mellitus Evidence drug abuse Unwilling contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Interferon</keyword>
	<keyword>Ribavirin</keyword>
</DOC>